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Summary 
Adenosine (I#M to l mM) depressed spontaneous transmitter release from 
frog motor nerve terminals without producing any observable postsynaptic effects. 
Since this action of adenosine was blocked by 20#M theophylline and I/~M 8- 
phenyltheophylline, adenosine probably acts at a specific receptor on motor nerve 
terminals to ~duce spontaneous transmitter output. The effects of the adenosine 
analogs, L-N"-phenylisopropyladenosine (L-PIA, 100pM to I~M), D-PIA (100riM 
to 100/~M), and 5'-N-ethylcarboxamidoadenosine (NECA, 10nM to 100/.~M), were 
tested on spontaneous transmitter release at the frog neuromuscular junction. L- 
PIA depressed mepp frequency at a threshold concentration of about l nM, was 
thirteen times more potent than NECA, and was 294 times more effective than D- 
PIA. The rank-order potency of these analogs indicates that adenosine acts at an 
Al- l ike receptor to depress spontaneous transmitter release. Inhibitory actions of 
maximally effective concentrations of adenosine and L-PIA were also blocked by 
the Al-Specific antagonist, l-3-dipropyl-8-cyclopentylxanthine (DPCPX) at a 
concentration of 100nM. Micromolar concentrations of NECA, an agonist with 
approximately equal affinity for the A 1 and A 2 receptors, produced biphasic 
effects on mepp frequency. Thus, a second adenosine receptor, perhaps of the A.2 
subtype, may be present on motor nerve terminals and may mediate an increase m 
spontaneous transmitter release. 
Adenosine may play an important role in the regulation of transmitter release from vertebrate 
motoneurons. ATP is stored with acetylcholine (ACh) in cholinergic synaptic vesicles in the 
Torpedo electric organ (17) and the rat caudate nucleus (33) and may also be stored in synaptic 
vesicles in vertebrate motoneurons. ATP is released with ACh from motor nerve terminals and 
may be hydrolyzed to adenosine in the synaptic cleft (31,37). In addition, ATP is released from 
contracting skeletal muscle (6). Thus, adenosine levels in the synaptic cleft may increase with 
increasing transmitter output. Silinsky (37) has estimated that the concentration of adenine 
nucleotides in the synaptic cleft may reach 100/~M following brief repetitive stimulation. This 
concentration is up to 100-fold greater than the doses necessary to produce physiological effects 
(38). Thus, adenosine, which is produced during neuronal stimulation, may play a feedback role 
in neuromuscular transmission. 
At the frog and rat neuromuscular junction (NMJ), adenosine decreases both evoked and 
spontaneous ACh release (7,20,32,38). Adenosine reduces the quantal content of endplate 
potentials (epps), which are evoked by nerve stimulation, and reduces the frequency of 
spontaneous miniature endplate potentials (mepps), which can be recorded in the absence of nerve 
stimulation. These actions are not accompanied by any observable postsynaptie effects. 
The depressant ef~cts  of adenosine on transmitter release may be mediated by specific 
adenosine receptors on motor nerve terminals. Two types of adenosine receptors, A 1 and A2, are 
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found on the plasma membrane of several cell types, including adipocytes, platelets, gila, and 
neurons ($,10,11,14,19,25,26,43). A 1 and A 2 receptors can be distinguished pharmacologically 
using the adenosine analogs, L-PIA, its stereoisomer D-PIA, and NECA. 
Ribiero and Scbastiio (29) have characterized the receptor involved in the inhibitory action 
of adenosine on evoked transmitter release at the frog NMJ. The effects of several adenosine 
analogs were studied on the amplitude of the nerve-evoked muscle twitch. Ribiero and Sebastifio 
reported that the rank-order potency of these analogs did not fit the criteria for an A l or A 2 
adenosine receptor and suggested that a third receptor, an A 3 receptor, may be present on motor 
nerve and other nerve terminals (30). They postulated further that adenosine may act at this 
receptor to block calcium entry through voltage-sensitive calcium channels in the nerve terminal 
membrane. In contrast, Silinsky has reported that adenosine depresses transmitter release from 
frog motoneurons by a mechanism which does not involve inhibition of calcium influx (38,41) or 
changes in the intracellular calcium concentration (22). Other investigators (7,20) have also 
reported that adenosine does not reduce calcium influx into motor nerve terminals. 
I have characterized the adenosine receptor which mediates a decrease in spontaneous 
transmitter release from frog motoneurons. Spontaneous transmitter release, unlike evoked 
transmitter output, is not dependent upon the influx of calcium ions through voltage-sensitive 
calcium channels. Instead, resting spontaneous transmitter release probably varies with the resting 
levels of calcium within the nerve terminal (1). The evidence presented below indicates that 
adenosine acts at an A l - l i ke  receptor to reduce spontaneous transmitter release from frog motor 
nerve terminals. Preliminary reports of some of this work have been published (2,3). 
Methods 
The cutaneous-pectoris nerve-muscle preparation was isolated from small frogs (Rana pipie~zs, 
1.5 to 2.5 inches, Kons Scientific, Germantown, Wisconsin). The nerve-muscle preparation was 
pinned out in a recording dish lined with Sylgard resin and continually perfused with frog Ringer 
( l lSmM NaCI, l.gmM CaCI 2, 2mM KCI, 5raM glucose, 5raM Tris HCi, pH 7.2). Intracellular 
recordings of mepps were made with 20-40Mf~ glass microelectrodes placed in the endplate region 
of the muscle fiber. Microelectrodes were usually filled with 3M KCI. In most cases, muscle 
resting potentials of about -95mV could be obtained for several hours. During the winter, 
however, the resting potential of the muscle fibers depolarized over time. The problem was 
corrected by filling the microelectrodes with a 250raM KCI solution as opposed to a 3M KCI 
solution. This change in the filling solution reduced the muscle resting potential by about 10mV 
but had no other effects on the experimental results. Recordings were made at 18-21°C. Bath 
temperature was controlled by a peltier device. In any one experiment, the temperature did not 
vary by more than l°C. Drugs were applied by perfusion. 
Mepps result from the spontaneous release of single quanta of ACh, often from the 
unstimulated motor nerve terminal. At the frog NMJ, mepps usually occur at a rate of 0.1 to 10 
per second. A change in mepp frequency which was not accompanied by a change in mepp size 
was interpreted as a change in spontaneous transmitter release (23). 
Data are presented from sixty-six experimental preparations in which mepp frequency 
remained stable for several hours. The mean values for mepp frequency recorded at a given 
endplate in normal Ringer varied by no more than 15% between the beginning and end of an 
experiment. To determine the baseline mepp frequency generally 10 minutes of continuous 
recordings were obtained. The continuous recording was divided into consecutive recording 
periods or bins of ten seconds duration, and the values for mepp frequency calculated for each 
recording bin were compared. If the mepp frequencies in each bin differed from each other by 
more than two-fold, then mepp frequency was considered too variable for further 
experimentation, and another endplate was sampled. Similarly, if mepps occurred in high 
frequency bursts, the endplate was rejected for further study. The baseline mepp frequency 
obtained in Figure 1 is an example of the most variable baseline mepp frequency used in these 
experiments. 
The effects on mepp frequency of adenosine agonists and antagonists were measured ten to 
twenty minutes after the drug had been introduced to the preparation, and the change in mepp 
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frequency had plateaued. Values for mean mepp frequencies in the presence of the drug were 
calculated by averaging the values for mepp frequency of a minimum of thirty consecutive ten- 
second recording bins. Following drug application, the preparation was washed in normal Ringer 
for a minimum of thirty minutes. If mepp frequency returned to a value within 15% of the 
baseline mepp frequency, then the effect of the agent was considered completely reversible. A 
second concentration of the drug or a different compound was then applied to the preparation. 
In five experiments, increasing concentrations of the same adenosine agonist were serially applied 
to the same endplate. At the end of the experiments, the preparations were washed with normal 
Ringer in order to ensure that baseline mepp frequency had returned to the pretreatment value. 
Mean mepp frequencies obtained from one endplate in the presence of the drug were 
compared to the pretreatment mepp frequency using the two-sample Student's t-test. In general, 
a change in mean mepp frequency of at least 20% was necessary to produce a statistically 
significant (p<0.05) change in mepp rate. 
The amplitudes of mepps were measured directly from the oscilloscope. Mepp amplitudes 
were divided into 0.2mV size bins, and the bins were plotted against the frequency of their 
occurrence. Mepp size histograms obtained from one endplate in different recording solutions 
were compared statistically using the Kolmogorov-Smirnov test (p<0.05). 
Adenosine and its analogs, L-PIA, D-PIA, and NECA, were dissolved directly into frog 
Ringer. Theophylline and 8-phenyltheophylline, at concentrations of 1 to 10raM, were dissolved 
in 0.IN NaOH and diluted with Ringer to a final concentration of 1 to 20#M. The A 1 specific 
antagonist, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), was dissolved at a concentration of 
100#M in 0.2N NaOH before dilution with Ringer to its final concentration. Adenosine and 
theophylline were obtained from Sigma Chemical Co. (St. Louis, Me); L-PIA, D-PIA, NECA, 
and DPCPX were purchased from Research Biochemicals, Inc. (Natick, MA). 
R¢~91t~  
Adenosine, in a concentration-dependent manner, reversibly reduced mepp frequency without 
affecting the muscle resting potential or mepp size (nffil4, Fig. 1). Thus, adenosine depressed 
spontaneous transmitter release from frog motor nerve terminals in the absence of any observable 
postsynaptic actions. 
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FIG h 
Adenosine (10pM) reversibly depressed mepp frequency but had no effect on mepp size. 
In (A), mepp frequencies for one minute recording periods were plotted against time. 
Adenosine reduced mepp frequency by 60% (p<0.001). In (B), the amplitudes of mepps 
were grouped into 0.2 mV size bins, and the bins were plotted against the frequency of 
their occurrence. Amplitude histograms were plotted after measuring 100 mepps in 
Ringer and 100 mepps in 10~M adenosine. Adenosine did not affect the amplitude 
distribution of the mepps (p>0.2). ADO ffi adenosine. 
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In one experiment, 50#M adenosine did not depress but enhanced mepp frequency by 43% 
(p<0.05). This effect was reversible. In a second experiment, lmM adenosine produced a 
transient increase followed by a sustained decrease in mepp frequency. Stimulatory effects of 
adenosine on neuromuscular transmission have also been reported by Silinsky (36). 
The inhibitory effect of adenosine on mepp frequency was mediated by an adenosine 
receptor. In three out of three experiments, the decrease in mepp frequency produced by 10#M 
adenosine was completely blocked by 20/~M theophylline, an adenosine receptor antagonist (12,35). 
At 20/~M, theophylline may produce a small increase in resting mepp frequency, but this effect 
was not statistically significant (4). Similarly, the adenosine antagonist, 8-phenyltheophylline, at 
I~M, reversed the inhibitory action of 2.5t~M adenosine (n=2 preparations). 
Theophylline and g-phenyltheophylline block both the A 1 and A 2 adenosine receptors with 
approximately equal affinity (14). In contrast, 1,3-dipropyl-g-cyclopentylxanthine (DPCPX) is a 
selective antagonist for the A 1 receptor. At a concentration of 100nM, DPCPX completely 
reversed the effects of 10/~M adenosine in one preparation and partially blocked adenosine's 
action in a second experiment. In four preparations, 100rim DPCPX reversed completely the 
inhibitory effects of 1/~M L-PIA, a potent Alagonis t ,  and partially inhibited L-PIA's action in a 
fifth (Fig. 2). The direct effects of 100nM DPCPX on mepp frequency were variable. DPCPX 
enhanced mean mepp frequency by 99% (p<0.05) in one of the seven experiments . In the other 
preparations, DPCPX produced both small increases and decreases in mepp frequency but these 
changes were not statistically significant. 
In one experiment, 10#M adenosine depressed mepp frequency by 23% (p<0.05) in the 
absence of DPCPX but enhanced mepp frequency by 105% (p<0.001) in the presence of 100nM 
DPCPX. DPCPX, in the absence of adenosine, also increased mepp frequency but only by 49% 
(p<0.05). Thus, DPCPX may have blocked an inhibitory effect and unmasked an excitatory 
action of adenosine. 















100nM DPCPX partially blocked the inhibitory effects of lpM L-PIA on spontaneous 
transmitter release. Data represent the mean values for mepp frequencies recorded from 
a single endplate. I#M L-PIA significantly depressed mepp frequency by 61% while 
I#M L-PIA in combination with 100nM DPCPX significantly reduced mepp frequency 
by only 34%. The difference between the values for mepp frequency in the presence of 
I#M L-PIA and in the presence of I#M L-PIA and 100nM DPCPX was statistically 
significant. 100nM DPCPX reduced mepp frequency by 23% but this effect was not 
significant. Please note that the action of I#M L-PIA was only partially reversible after 
thirty minutes of washing with Ringer. 
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The adenosine analogs, L-PIA, D-PIA, and NECA, all reduced mepp frequency without 
affecting the muscle's resting potential or mepp size. To construct a concentration-response curve 
(Fig. 3), the data from forty-six experiments were pooled. The data from four to seven different 
endplates were used to construct each point of the concentration-response curve. 
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FIG. 3: 
Concentration-response curves for the depressant effect of L-PIA, NECA, adenosine, 
and D-PIA on mepp frequency. Each point represents the mean _+ SEM of changes in 
mepp frequency recorded from four to seven endplates. In these experiments, the only 
action of adenosine, L-PIA, and D-PIA was to reduce mepp frequency. In contrast, 
NECA, at concentrations at or above I/~M, produced transient (one minute) increases in 
mepp frequency which were preceded or followed by more prolonged reductions in 
mepp rate. The percent depression in mepp frequency due to NECA was calculated for 
the periods during which mepp frequency was depressed. ADO = adenosine. 
L-PIA was the most potent adenosine analog in depressing mepp frequency. At a 
concentration as low as lnM, L-PIA depressed mepp frequency by a mean of 17% while at 10nM, 
L-PIA produced a maximal reduction in mepp rate. The greatest reduction in mepp frequency 
produced by adenosine and its analogs was about 50%. The concentrations which produced half- 
maximal effects were measured from the concentration-response curves (Fig. 3) to be 5.1nM for 
L-PIA, 68nM for NECA, 460riM for adenosine, and 1500nM for D-PIA. Thus, L-PIA was 13 
times more potent than NECA and 294 times more potent than D-PIA in reducing spontaneous 
ACh release. The rank order potency of adenosine analogs in depressing mepp frequency was L- 
PIA>NECA>adenosine>D-PIA. 
The effects of L-PIA and D-PIA on mepp frequency differed from the actions of NECA in 
at least three ways. Effects of NECA (100nM to 100#M) were completely reversible. In contrast, 
the effects of L-PIA and D-PIA completely reversed at concentrations below I#M but only 
partially reversed, after thirty minutes, at concentrations of I#M, 10/~M, and 100#M. 
The actions of L-PIA and D-PIA on mepp frequency were concentration-dependent at all 
concentrations tested. NECA depressed mepp frequency in a concentration-dependent manner at 
concentrations at or below I#M. However, the depressant effect of NECA at 10#M were less 
than that seen at lower concentrations, probably because, at submicromolar concentrations, NECA 
produced only an inhibitory effect on mepp frequency while, at mieromolai" concentrations, 
NECA both inhibited and stimulated spontaneous transmitter release. In four out of four trials, 
application of I#M NECA produced an initial enhancement followed by a sustained reduction in 
mepp frequency (Fig. 4a). With 10/~M NECA, decreases in mepp rate were preceded or followed 
by oscillatory changes in frequency in two out of five experiments (Fig. 4b). At 100#M, the only 
effect of NECA was to reduce mepp frequency in three experiments but, in one preparation, the 
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depression in mepp frequency was preceded ~T an enhanced rate of mepps. Oscillations in mepp 
frequency produced by micromolar concentrations of NECA were two to three times greater than 
the variations in mepp frequency observed in normal Ringer. Thus, NECA, at concentrations at 
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FIG. 4: 
Bimodal effects of NECA on mepp frequency. NECA, at concentrations of I#M (A) 
and 10/JM (B) both enhanced and depressed mepp frequency. Mepp frequencies for 
fifty-second (A) or thirty second (B) recording periods were plotted against time. 
Even in those preparations in which NECA produced only a depressant effect on mepp 
frequency, the inhibitory effects of 10 and 100#M NECA developed more slowly than the actions 
of adenosine, L-PIA, D-PIA, or 100nM NECA. The time period from the introduction of the 
drug to a steady-state change in mepp frequency was estimated from the plots of mepp frequency 
against time. The effects of adenosine, L-PIA, D-PIA and 100nM NECA reached a steady-state 
within two to four minutes. Values varied from 2.0 ± 1.0 minutes (mean ± SEM) for I/~M D-PIA 
to 4.3 ± 1.9 minutes for 5nM L-PIA. In contrast, the inhibitory actions of 10/~M and 100#M 
NECA did not develop for an average of 17 _+ 3.6 minutes and 7.0 ± 1.5 minutes respectively. 
This delay in NECA's inhibitory action may indicate that NECA is producing more than one 
effect on spontaneous transmitter release. 
Discussion 
The relative effectiveness of L-PIA, D-PIA, and NECA in reducing mepp frequency 
indicates that adenosine acts at an Al- l ike receptor to depress spontaneous transmitter output 
from frog motoneurons. L-PIA decreased mepp frequency at a threshold concentration of about 
lnM and produced maximal effects at a concentration of 10nM. L-PIA acts at nanomolar 
concentrations at A 1 but not A 2 receptors (14,19,25,43,44). The difference in potency of the 
stereoisomers, L-PIA and D-PIA, in reducing spontaneous release was about 300-fold. High 
stereoselectivity for L-PIA over D-PIA is a characteristic of A 1 but not A 2 receptors 
(8,12,14,42). Finally, L-PIA was about thirteen times more potent than NECA at depressing 
spontaneous transmitter release. At A 1 receptors, L-PIA is more active than NECA while the 
reverse is true at A 2 receptors (14,19,25). 
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The effects of DPCPX at the frog neuromuscular junction also support the hypothesis that 
adenosine reduces spontaneous release at an Al- l ike adenosine receptor on frog motoneurons. 
Inhibitory actions of maximally-effective concentrations of adenosine and L-PIA were blocked by 
100nM DPCPX. In rat whole brain membranes, DPCPX binds with 700 times greater affinity to 
the A l as opposed to the A 2 receptor (9). In these membranes, at a concentration of 100riM, 
DPCPX binds almost exclusively to the A 1 receptor (24). 
In other nerve cells, the A 1 adenosine receptor is coupled to G i, a pertussis toxin-sensitive 
guanine nucleotide-binding protein (16). Pertussis toxin blocks the inhibitory effects of adenosine 
on spontaneous and evoked transmitter release in rat and frog motor nerve terminals (41). These 
data support the hypothesis that adenosine depresses ACh output from motor nerve terminals by 
activation of an A 1 receptor. 
The rank-order potency of adenosine analogs in depressing mepp frequency is different than 
the rank-order potency of these analogs in reducing the nerve-evoked twitch of the frog sartorius 
muscle as reported by Ribiero and Sebastiao (29). The half-maximal concentrations for effects of 
L-PIA and NECA on the nerve-evoked twitch were higher than those reported here for effects 
on mepp frequency. These investigators also found that L-PIA and NECA were almost 
equipotent in depressing twitch tension, and that L-PIA was only ten times more effective than 
D-PIA. Since the rank-order potency for these analogs in depressing evoked release did not 
match the rank-order potency for the A |  or A2. subtype, Riheiro and Sebastiao suggested that a 
third receptor, the A 3 receptor, may mediate inhlbitlon of evoked ACh release. 
The differences between my data and those of Ribeiro and Sebasti~o may result from 
differences in the species of frogs, the nerve-muscle preparations, or the compositions of the 
Ringer that were used. Alternatively, the differences may result from the different methods used 
to measure neuromuscular transmission. I measured spontaneous transmitter release by observing 
the frequency of mepps at single endplates, while Ribeiro and Sebastiio measured evoked 
transmitter release by measuring the size of the nerve-evoked twitch produced, not at a single 
endplate, but in the whole muscle. This difference may explain why L-PIA, NECA, and 
adenosine were less potent in reducing the nerve-evoked twitch than in depressing mepp 
frequency. The neuromuscular junction possesses a higher safety factor of transmission (21). 
Following an action potential in the motoneuron, more ACh is released than is necessary to 
produce an action potential or twitch in the muscle fiber. Before an effect on twitch tension will 
be observed, adenosine or its analogs must depress evoked transmitter release to a level below the 
safety factor. Thus, the concentration of adenosine necessary to reduce twitch tension in the 
whole muscle may be greatei than that necessary to reduce spontaneous release at a single 
endplate. 
It is also possible that adenosine, its agonists, and antagonists exert direct effects on twitch 
tension development. We have found that the adenosine receptor antagonist, aminophylline, 
significantly enhances twitch tension in the directly-stimulated frog semitendinosus muscle at a 
concentration as low as 25~M (34). This direct effect of aminophylline on muscle force 
generation may result from adenosine receptor blockade (28). 
Adenosine may inhibit evoked and spontaneous ACh release by different receptors or 
different mechanisms (30). However, Ribeiro and his co-workers have found that the A l-  
specific antagonist, DPCPX, blocks adenosine-induced inhibition of evoked ACh release from the 
rat phrenic nerve (13) while I have found that DPCPX reverses adenosine-induced depression of 
spontaneous release. The results of these experiments suggest that inhibition of evoked and 
spontaneous release may be mediated by the same receptor. My results also indicate that 
adenosine inhibits spontaneous ACh release at an A 1 receptor and stimulates spontaneous ACh 
release perhaps at a second receptor of the A 2 subtype (see below). The A 3 receptor described by 
Ribeiro and Sebasti[lo (29,30) may actually represent a combination of the A 1 and A 2 receptors 
(39). 
At A 1 receptors in platelet, fat, and brain cells, adenosine depresses adenylate cyclase activity 
(19,25,43,44). Adenosine may decrease mepp frequency by acting at an A 1 receptor to reduce 
adenylate cyclase activity and, thus, cyclic AMP levels in motor nerve terminals. However, an 
increase in cyclic AMP levels in motoneurons has been reported both to enhance (18,27,45) and 
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depress (38) transmitter release. Further studies are necessary to determine whether adenosine 
acts at an A 1 receptor on motor nerve terminals to depress adenylate cyclase activity, and whether 
consequent changes in neuronal cyclic AMP levels affect spontaneous transmitter release. 
Finally, NECA, an agonist with approximately equal affinity for the A 1 and A 2 receptor, 
produced biphasic effects on spontaneous transmitter release. Silinsky and his co-workers (36,40) 
have also reported biphasic or stimulatory effects on mepp frequency of adenosine and its 
analogs. These data indicate that adenosine may exert a second, excitatory action on spontaneous 
transmitter output. 
Results from other experiments also suggest that adenosine stimulates ACh release from 
motonerurons. In one out of three experiments, adenosine, in combination with the Al-Specific 
antagonist, DPCPX, stimulated spontaneous transmitter output. Ribeiro and his co-workers (13) 
have also reported excitatory effects of NECA on evoked release at the rat NMJ when NECA was 
applied in the presence of DPCPX. Thus, DPCPX may block adenosine's inhibitory action on 
ACh release and unmask an excitatory effect of adenosine. Blockade of adenosine's inhibitory 
actions with pertussis toxin also reveals excitatory effects of adenosine (40). Finally, studies using 
adenosine antagonists suggest that adenosine stimulates spontaneous release. For example, in 
hyperosmotic Ringer, theophylline (10/~M) and adenosine deaminase (0.1 to 0.5 units/ml) 
depressed mepp frequency by blocking an excitatory action of endogenously-present adenosine 
(4). 
NECA both inhibited and stimulated mepp frequency in the micromolar concentration range 
which is the range in which NECA is active at the A 2 receptor in other cell types (14,25). 
Bimodal effects of adenosine and NECA on adenylate cyclase activity have been observed on 
platelet (26), cultured glial (44), and retinal cells (5). Biphasic effects probably result from the 
existence of both A 1 and A 2 receptors on these cells. Thus two adenosine receptors may be 
present on frog motor nerve terminals. At an A 1 receptor, adenosine may inhibit while, at a 
second receptor, perhaps of the A 2 subtype, adenosine may stimulate spontaneous transmitter 
release. 
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